on MEDINCELL (EPA:MEDCL)
Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes
Medincell, located in Montpellier, France, has upgraded its revenue forecast for its U.S.-marketed drug UZEDY®, a subcutaneous risperidone treatment for schizophrenia. Initially projected at around $160M, revenue expectations for 2025 have now been raised to $190-$200M. Teva Pharmaceuticals, Medincell’s partner, reported Q2 2025 sales of $54M, marking a 2.2-fold increase from Q2 2024, with H1 2025 sales at $93M, a 2.3-fold rise compared to H1 2024.
The Olanzapine Long-Acting Injectable (LAI), another Medincell prospect, completed its Phase 3 trial with positive efficacy results, free of PDSS, a significant complication. An NDA for this treatment is slated for Q4 2025, aiming to enhance schizophrenia management with improved safety and accessibility.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDINCELL news